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Abstract. Preoperative neoadjuvant chemotherapy (NAC) is 
considered to be the standard treatment for locally-advanced 
breast carcinomas. Obtaining precise information regarding 
the tumor extent and distribution by imaging modalities to 
assess the success of breast-conserving surgery following 
NAC is extremely important. Analysis of the detailed radio-
pathological correlation of magnetic resonance imaging (MRI) 
following NAC has not been reported previously. The MRI and 
histopathological shrinkage patterns of residual breast carci-
nomas in 27 consecutive cases were analyzed following NAC 
and classified into five categories: Types I and II (concentric 
shrinkage with and without surrounding lesions, respectively); 
type III (shrinkage with residual multinodular lesions); 
type IV (diffuse contrast enhancement in whole quadrant); 
and non-visualization. The present study clearly demonstrated 
that the most common MRI shrinkage pattern was type I 
(11 cases), followed by type II and non-visuali zation, and the 
most common histopathological shrinkage pattern was type II 
(11 cases), followed by type III (8 cases). The concordance 
rate between MRI and pathological patterns was 48% and the 
worst concordance MRI pattern was type I. MRI is considered 
to be a useful method for evaluation of the residual carcinoma 
following NAC. However, the concordance rate was low in the 
MRI pattern I cases and tiny foci of residual carcinoma were 
present in half of the non-visualization cases, as shown by 
MRI. Therefore, the tumor extent must be completely resected 
for patients who undergo NAC, and postoperative radiation 
may be important for preventing local recurrence of breast 
carcinoma.
Introduction
Preoperative neoadjuvant chemotherapy (NAC) is considered 
the standard treatment for locally-advanced breast carci-
nomas (1-6). Several large randomized clinical studies have 
shown that NAC is effective as an adjuvant chemotherapy 
and permits breast-conserving surgery (1-6). The current 
roles of NAC include control and downstaging of primary 
breast tumors, as well as reducing micrometastatic diseases. 
Therefore, it is extremely important to obtain precise informa-
tion regarding the extent and distribution of residual breast 
carcinomas following NAC by imaging modalities to assess 
the success of breast-conserving surgery.
Findings of previous studies have demonstrated the useful-
ness of imaging modalities for determining the tumor distribution 
of residual breast carcinoma following NAC (7-12). A study by 
Tozaki et al (9) analyzed computed tomography (CT) findings 
of tumor distribution patterns of locally-advanced breast carci-
nomas prior and subsequent to NAC. The distribution patterns 
of the enhancing lesions of breast carcinomas prior to NAC were 
classified into five categories: Solitary, grouped, separated, mixed 
and replaced lesions; and the shrinkage patterns subsequent to 
NAC were classified into three categories: Concentric shrinkage 
with or without surrounding lesions and shrinkage with residual 
multinodular lesions (9). The study concluded that CT classifica-
tion of tumor distribution prior to NAC and shrinkage patterns 
subsequent to NAC is important for the evaluation of the residual 
lesions undergoing breast-conserving surgery (9). In addition, 
Kim et al (12) recently reported magnetic resonance imaging 
(MRI) patterns of breast carcinomas prior and subsequent to 
NAC, and analyzed the correlation with pathological response 
grading. The shrinkage patterns of breast carcinomas following 
NAC were classified into five categories: Type I (concentric 
shrinkage without any surrounding lesion); type II (concen-
tric shrinkage with surrounding lesions); type III (shrinkage 
with residual multinodular lesions); type IV (diffuse contrast 
enhancement in whole quadrant); and non-visualization (12). The 
study concluded that the type I pattern was the most frequently 
observed in the pathological responder group and type IV was 
more frequently found in the non-responder group (12).
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However, thus far, the analysis of the detailed radiopatho-
logical correlation of MRI prior and subsequent to NAC for 
breast carcinomas has not been reported. In the present study, 
a detailed analysis of the radiopathological correlation of 
residual breast carcinomas following NAC is reported, and the 
usefulness of MRI subsequent to NAC for breast-conserving 
surgery is discussed.
Materials and methods
Case selection. The study included 27 consecutive cases of 
breast carcinomas. The subjects who underwent NAC at 
Department of Surgery, Shiga University of Medical Science 
(Otsu, Shiga, Japan). In 20 cases, MRI was performed prior and 
subsequent to NAC, and in the remaining seven cases, MRI 
was performed only following NAC and CT was performed 
prior to NAC.
The mean age of the patients was 48.4 years (range, 
29-66 years). All the patients in the study were female. Table I 
shows the clinical features of the 27 cases.
The NAC regimens used were: taxane in five, taxane + anthra-
cycline in 18 and taxane + anthracycline + trastuzumab 
in four cases. Mastectomy was performed in 9 cases and 
breast-conserving surgery was performed in 18 cases.
MRI technique. MRI was performed using 1.5T- and 3T-scanners 
(Signa HD; GE Healthcare, Milwaukee, WI, USA) with the 
use of a dedicated breast coil. Patients underwent imaging 
in the prone position with breasts immobilized. Contrast 
material was injected in all the patients (0.1 mmol/kg gado-
pentetate dimeglumine). The contrast-enhancement pattern 
was analyzed in the early phase.
CT technique. CT was obtained on a 64- (Aquilion CX; Toshiba 
Medical Systems, Otawara, Japan) or a 320-multidetector CT 
scanner (Aquilion ONE; Toshiba Medical Systems). Contrast 
material was injected in all the patients (100 ml of non-ionic 
contrast material).
Interpretation of MRI or CT findings. Four breast surgeons 
performed a consensus review of the breast MRI or CT exami-
nations in all the cases. The initial contrast-enhancement 
pattern of breast carcinoma by MRI or CT prior to NAC was 
classified into five categories as suggested by Tozaki et al (9), 
i.e., solitary; grouped (localized lesion with linear, spotty, or 
linear and spotty enhancement); separated (multiple foci of 
contrast enhancement); mixed (grouped lesion with multiple 
foci); and replaced lesions (diffuse contrast enhancement in 
whole quadrant) (Fig. 1A).
The shrinkage pattern of breast carcinoma by MRI 
following NAC was classified into five categories as suggested 
by Kim et al (12): Type I (concentric shrinkage without 
any surrounding lesion); type II (concentric shrinkage with 
surrounding lesions); type III (shrinkage with residual multi-
nodular lesions); type IV (diffuse contrast enhancement in 
whole quadrant); and non-visualization (Fig. 1B).
Histopathological evaluation. The histopathological diag-
nosis of breast carcinomas prior and subsequent to NAC was 
independently performed by two diagnostic pathologists. The 
histopathological tumor regression pattern was semi-quanti-
tatively evaluated using the Miller-Payne grading system as 
follows (13): Grade 1, no change or particular alteration to indi-
vidual malignant cells and no reduction in overall cellularity; 
grade 2, minor loss of tumor cells (≤30%) but overall cellu-
larity remained high; grade 3, between an estimated 30-90% 
reduction in tumor cells; grade 4, a marked disappearance of 
tumor cells such that only small clusters or widely dispersed 
individual cells remained with a >90% loss of tumor cells; and 
grade 5, no malignant cells identified in sections from the tumor 
site and only vascular fibroelastic stroma that often contains 
macrophages remains. However, intraductal components may 
be present (13). Patients showing Miller-Payne grades 3, 4 or 5 
were classified as responders and patients showing grades 1 
or 2 were classified as non‑responders.
The histopathological pattern of the residual carcinoma 
was also classified by the same method as the MRI shrinkage 
pattern as suggested by Kim et al (12) (Fig. 1B).
Results
MRI or CT findings prior to NAC. Table II shows the 
initial enhancement patterns of MRI or CT of 27 cases of 
breast carcinomas prior to NAC. The most common initial 
contrast-enhancement pattern was solitary (18 cases) (Fig. 2A). 
The second most common pattern was grouped (five cases) 
(Fig. 2B), followed by separated (three cases) (Fig. 2C) and 
replaced patterns (one case) (Fig. 2D). There was no case 
showing a mixed pattern in the present study.
Histopathological findings of the biopsy specimen prior to 
NAC. All the cases were diagnosed as invasive ductal carci-
noma of no special type by the biopsy specimen. No special 
type of invasive breast carcinoma, such as invasive lobular or 
mucinous carcinomas, was included in the present study.
MRI findings following NAC. Table II summarizes the MRI 
findings of the shrinkage patterns of breast carcinomas 
Table I. Clinical characteristics of breast carcinomas.
Characteristics No. of cases (%)
Initial clinical stage
  I 1 (4)
  IIA 7 (26)
  IIB 17 (63)
  IIIA 2 (7)
  IIIB 0 (0)
  IIIC 0 (0)
  IV 0 (0)
Surgical method
  Radical mastectomy 9 (33)
  Partial mastectomy 18 (67)
Neoadjuvant chemotherapy regimen
  Taxane 5 (18)
  Taxane + anthracycline 18 (67)
  Taxane + anthracycline + trastuzumab 4 (15)
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following NAC and the correlation between the initial 
contrast-enhancement patterns prior to NAC and the shrinkage 
patterns following NAC. The most common shrinkage pattern 
identified was type I (11/27 cases) (Fig. 3A). The second most 
common patterns identified were type II and non‑visualization 
(6 cases each) (Fig. 3B and C). Three cases showed a type III 
pattern (Fig. 3D), while only one case showed type IV 
(Fig. 3E).
The most common shrinkage pattern of solitary lesions 
prior to NAC was type I (9/18 cases), in contrast to grouped 
lesions, which demonstrated that the non-visualization pattern 
(3/5 cases) was the most frequent. The replaced lesion showed 
the type IV shrinkage pattern.
Figure 1. Illustrated models of the initial enhancement and shrinkage patterns. (A) Initial enhancement patterns prior to neoadjuvant chemotherapy. Solitary, 
grouped, separated and replaced patterns. (B) Shrinkage patterns following neoadjuvant chemotherapy. Type I, concentric shrinkage without any surrounding 
lesion; type II, concentric shrinkage with surrounding lesions; type III, shrinkage with residual multinodular lesions; and type IV, diffuse contrast enhance-
ment in whole quadrant.
  A
  B
Figure 2. Magnetic resonance imaging of the initial enhancement patterns of breast carcinomas prior to neoadjuvant chemotherapy. (A) Solitary; (B) grouped; 
and (C) separated lesions. The arrow (inset) shows the daughter nodule. (D) Replaced lesion.
Table II. Correlation between initial contrast-enhancement 
patterns prior to neoadjuvant chemotherapy and shrinkage 
patterns.
 Initial enhancement patterns
 -----------------------------------------------------------------------------------------
Shrinkage patterns Solitary Grouped Separated Replaced
Non-visualization 2 3 1 0
Type I 9 1 1 0
Type II 5 1 0 0
Type III 2 0 1 0
Type IV 0 0 0 1
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Histopathological findings following NAC. Table III summa-
rizes the Miller-Payne grading system of the present study. 
The most common histopathological regression grade was 
grade 3 (10/27 cases). In four cases showing grade 5, no viable 
carcinoma cells and no residual intraductal component were 
observed in these cases. The rate of responder cases was 
70.4% (19/27 cases) and that of non-responders was 29.6% 
(8/27 cases).
Table IV shows the radiopathological correlation of the 
shrinkage patterns of breast carcinomas following NAC in 
the study. The most common pathological shrinkage pattern 
of the residual carcinoma was type II (11/27 cases) (Fig. 4A), 
followed by type III (8 cases) (Fig. 4B). The concordance rate 
between the MRI pattern following NAC and pathological 
pattern was 48%: Non-visualization, three cases; type I, three 
(Fig. 4C); type II, four; type III, two; and type IV, one case 
(Fig. 4D). The worst concordance MRI pattern was type I as 
only three of the 11 cases corresponded to the pathological 
pattern, while four cases showed pathological type II and three 
cases showed pathological type III. In the residual carcinoma 
nodules, scar, accumulation of macrophages and hemosiderin 
deposition were observed in the cases showing MRI pattern 
type I and pathological pattern type II or III (Fig. 4E).
In the cases showing non-visualization by MRI following 
NAC, three of the six cases had no residual carcinoma by 
pathological examination and the remaining cases had only a 
few residual carcinomas by pathological examination, which 
showed pathological types II (two cases) and III (one case) 
(Fig. 4F).
Follow‑up information subsequent to surgery. No local recur-
rence was observed in any of the 27 patients (median follow-up 
period, 32.9 months; range, 6-88 months).
Discussion
NAC is widely performed for patients with locally-advanced 
breast carcinomas in order to control and downstage the 
primary breast carcinomas. Therefore, accurate assess-
ment regarding the extent and distribution of the residual 
breast carcinomas following NAC by imaging modalities is 
extremely important to assess the success of breast-conserving 
surgery. However, it has been reported that MRI and CT often 
over- or underestimate the extent and distribution of residual 
carcinomas following NAC (7-12).
A study by Tozaki et al (9) analyzed the usefulness of 
determining the breast carcinoma distribution prior to NAC 
and the shrinkage patterns following NAC by multidetector 
CT. The study evaluated 47 consecutive locally-advanced 
breast carcinomas from 46 patients and classified the distribu-
tion patterns of contrast enhancement prior to NAC by CT into 
5 categories: Solitary; grouped; separated; mixed; and replaced 
lesions (9). Solitary lesions were observed in 15 cases, grouped 
in 12, separated in four, mixed in five and replaced in 11 cases 
in the series (9). The rates of grouped and replaced lesions in 
the present study were low compared to the series reported 
by Tozaki et al (9) [18.5% were grouped lesions in the present 
study vs. 25.5% in the study by Tozaki et al (9) and 3.7% were 
replaced lesion in the present study vs. 23.4% in the study by 
Tozaki et al (9)]. However, the rates of the initial enhancement 
patterns as reported by Kim et al (12), who also classified the 
initial enhancement patterns of MRI using the same methods 
suggested by Tozaki et al (9), fundamentally corresponded to 
the results of the present study. This difference may be due to 
a relatively high percentage of inflammatory carcinomas in the 
study reported by Tozaki et al (9).
Tozaki et al (9) also classified the shrinkage patterns with 
non-replaced lesions following NAC as concentric shrinkage 
with or without surrounding lesions, and shrinkage with 
residual multinodular lesions. The most common shrinkage 
pattern was concentric shrinkage without any surrounding 
lesions (16/28 cases showing complete or partial response 
by CT), followed by shrinkage with residual multinodular 
lesions (five cases), complete response (four cases) and concen-
tric shrinkage with surrounding lesions (three cases) (9). 
Furthermore, the study also reported that the assessment of 
the tumor extent following NAC by CT and histopathological 
examination of the residual carcinoma revealed that a devia-
tion of <2 cm in diameter was found in 88% of cases (14/16), 
showing a pattern of concentric shrinkage without any 
surrounding lesions; 100% of cases (3/3), who had a pattern of 
concentric shrinkage with surrounding lesions; and none of the 
cases (0/5) demonstrating a pattern of shrinkage with residual 
multinodular lesions (9). The cases showing a difference of 
>2 cm in length from the histopathological examination were 
all underestimated, while no cases of overestimation were 
present in the study. Therefore, Tozaki et al (9) concluded 
that CT classification of shrinkage patterns following NAC 
is useful for evaluation of the residual lesions for undergoing 
breast-conserving surgery, particularly in the cases showing 
concentric shrinkage with or without surrounding lesions (9). 
However, CT underestimated the residual tumor extent by 
>2 cm in the cases showing shrinkage with residual multinod-
ular lesions (9). Therefore, a residual carcinoma in the surgical 
margins from the breast-conserving surgery is an extremely 
critical issue in these cases.
Recently, Kim et al (12) analyzed the MRI patterns of 
56 consecutive breast carcinomas from 55 patients prior and 
subsequent to NAC and evaluated the correlation with patho-
logical response grading. The shrinkage patterns of breast 
carcinomas following NAC were classified into five categories: 
Type I (concentric shrinkage without any surrounding lesion); 
type II (concentric shrinkage with surrounding lesions); 
type III (shrinkage with residual multinodular lesions); 
type IV (diffuse contrast enhancement in whole quadrant); 
and non-visualization (12). In that study, the most common 
shrinkage pattern was type I (29/56 cases), followed by type II 
(13 cases), type III (5 cases), type IV (4 cases) and non-visu-
Table III. Miller-Payne grading of the present study.
Grade No. of cases
1   1
2   7
3 10
4   5
5   4
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Figure 3. Magnetic resonance imaging of the shrinkage patterns of breast carcinomas following neoadjuvant chemotherapy. (A) Type I showing concentric 
shrinkage without any surrounding lesion. (B) Type II showing concentric shrinkage with surrounding lesions. (C) Non-visualization. (D) Type III showing 
shrinkage with residual multinodular lesions. (E) Type IV showing diffuse contrast enhancement in the whole quadrant.
Table IV. Correlation between magnetic resonance imaging (MRI) shrinkage patterns and pathological patterns following neo-
adjuvant chemotherapy.
 Pathological patterns
 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
MRI patterns Nonvisualization Type I Type II Type III Type IV
Non-visualization 3 0 2 1 0
Type I 1 3 4 3 0
Type II 0 0 4 2 0
Type III 0 0 1 2 0
Type IV 0 0 0 0 1
Figure 4. Panoramic view of the histopathological shrinkage patterns and features following neoadjuvant chemotherapy. (A) Pathological type II showing 
concentric shrinkage with surrounding lesions. (B) Pathological type III demonstrating shrinkage with residual multinodular lesions. (C) Pathological type I 
showing concentric shrinkage without any surrounding lesion. (D) Pathological type IV demonstrating multiple residual carcinomas (arrows, residual car-
cinoma cells); hematoxylin and eosin staining. (E) Scar, accumulation of macrophages and hemosiderin deposition are observed in the residual carcinoma 
nodules; hematoxylin and eosin staining (magnification, x40). (F) Only a few residual degenerative carcinoma cells are present within the scar and accumula-
tion of macrophages; hematoxylin and eosin staining (magnification, x40).
  A   B
  C   D
  E   F
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alization (3 cases) (12). The study concluded that type I was 
more frequently observed in the pathological responder group 
and type IV was more frequently noted in the non-responder 
group (12). Although the ratio of non-visualization was rela-
tively high in the present study (22%), the shrinkage patterns 
fundamentally corresponded to the results in the study by 
Kim et al (12).
To the best of our knowledge, the present study reports 
the first analysis regarding the radiopathological correlation 
between MRI shrinkage patterns subsequent to NAC and 
pathological residual tumor patterns. The histopathological 
patterns of the residual carcinoma following NAC were clas-
sified by the same method as the MRI shrinkage patterns 
suggested by Kim et al (12), as shown in Fig. 1B (13). The 
notable findings of the present study were: i) The most common 
histopathological shrinkage pattern was type II (11/27 cases), 
followed by type III (eight cases); ii) the concordance rate 
between MRI patterns following NAC and pathological 
patterns was 48%; and iii) the worst concordance MRI pattern 
was type I (3/11 cases).
Of the eight cases showing type I MRI and non-type I 
pathological patterns, four cases showed pathological type II 
and three cases showed pathological type III. This indicates 
that the residual tumor following NAC appeared as a concen-
tric tumorous lesion without any surrounding lesions by MRI. 
However, histopathologically it did not form a tumorous lesion, 
but it was surrounded by a few or multinodular residual lesions 
and harboured fibrous scar with hemosiderin deposition and 
the accumulation of macrophages among the multinodular 
residual carcinoma nests, as shown in Fig. 4E. This may reflect 
a multifocal tumor shrinkage but not a concentric shrinkage 
pattern by NAC. In addition, of the six cases showing 
non-visualization by MRI following NAC, three cases had 
no residual carcinoma by pathological examination and the 
remaining cases had residual carcinoma, which were patho-
logical types II (two cases) and III (one case). This may be 
due to the small amounts of residual carcinoma, as shown in 
Fig. 4F, which could not be detected by MRI.
In conclusion, the radiopathological correlation of breast 
carcinomas was analyzed prior and subsequent to NAC. MRI 
is considered to be a useful method for evaluating residual 
carcinomas following NAC (the concordance rate was 48%). 
However, in the cases with MRI pattern I, the concordance 
rate was low and multinodular residual carcinomas were 
frequently present. Additionally, tiny foci of residual carci-
noma were present in half of the non-visualization cases 
by MRI. Therefore, the tumor extent prior to NAC must be 
completely resected for patients who undergo NAC, particu-
larly those with MRI patterns of type I, and non-visualization 
and postoperative radiation therapy may be important for 
preventing local recurrence of breast carcinomas.
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